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Abstract
Background: MicroRNA (miRNA) control key elements of mRNA stability and likely contribute to the dysregulated
lung gene expression observed in systemic sclerosis associated interstitial lung disease (SSc-ILD). We analyzed
the miRNA gene expression of tissue and cells from patients with SSc-ILD. A chronic lung fibrotic murine model
was used.
Methods: RNA was isolated from lung tissue of 12 patients with SSc-ILD and 5 controls. High-resolution computed
tomography (HRCT) was performed at baseline and 2–3 years after treatment. Lung fibroblasts and peripheral blood
mononuclear cells (PBMC) were isolated from healthy controls and patients with SSc-ILD. miRNA and mRNA were
analyzed by microarray, quantitative polymerase chain reaction, and/or Nanostring; pathway analysis was performed
by DNA Intelligent Analysis (DIANA)-miRPath v2.0 software. Wild-type and miR-155 deficient (miR-155ko) mice were
exposed to bleomycin.
Results: Lung miRNA microarray data distinguished patients with SSc-ILD from healthy controls with 185 miRNA
differentially expressed (q < 0.25). DIANA-miRPath revealed 57 Kyoto Encyclopedia of Genes and Genomes pathways
related to the most dysregulated miRNA. miR-155 and miR-143 were strongly correlated with progression of the
HRCT score. Lung fibroblasts only mildly expressed miR-155/miR-21 after several stimuli. miR-155 PBMC expression
strongly correlated with lung function tests in SSc-ILD. miR-155ko mice developed milder lung fibrosis, survived
longer, and weaker lung induction of several genes after bleomycin exposure compared to wild-type mice.
Conclusions: miRNA are dysregulated in the lungs and PBMC of patients with SSc-ILD. Based on mRNA-miRNA
interaction analysis and pathway tools, miRNA may play a role in the progression of the disease. Our findings
suggest that targeting miR-155 might provide a novel therapeutic strategy for SSc-ILD.
Keywords: Systemic Sclerosis, Lung fibrosis, Gene expression, microRNA, Biomarker, miR-155, Bleomycin
Background
Systemic sclerosis (SSc) is a chronic autoimmune disease
in which pulmonary involvement, particularly interstitial
lung disease (SSc-ILD), is known to be the leading cause
of mortality [1–3]. The prevalence of SSc-ILD is high
and approximately 15–30 % of patients will progress to
severe lung fibrosis. However, distinguishing those who
will progress from those who will have slow or stable
disease remains challenging [4, 5]. Using mRNA expres-
sion analysis of lung tissue in a prospective cohort of
patients with SSc-ILD, we recently described immune
activation pathways and upregulated transforming
growth factor-β (TGFβ)-induced signature genes associ-
ated with progressive lung fibrosis [6].
MicroRNA (miRNA) are small RNA that are of vital im-
portance in regulating gene expression within cells, having
critical roles in innate and adaptive immunity in general
[7]. In addition, there is increasing evidence they play a
role in fibrosis and are strongly associated with the
pathogenesis of a wide range of human diseases [8, 9].
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miRNA are remarkably stable and reliable for detection
in the blood and urine and bring new hope to the deve-
lopment of clinical biomarkers. More importantly,
disease-associated miRNA represent a new class of
therapeutic targets.
Using high-throughput technology, we show that
many miRNA are dysregulated in the lungs of patients
with SSc-ILD. In addition, selected miRNA are associ-
ated with progressive lung fibrosis based on image lung
score and lung function tests, with miR-155 as one of
the best markers. miR-155-deficient mice survive longer
and develop milder lung fibrosis. Therefore, miR-155
could be a potential novel therapeutic target for lung
fibrosis in patients with SSc.
Methods
Study participants
Between January 2002 and July 2004, 28 consecutive
patients with SSc-ILD, identified on HRCT as having
associated respiratory symptoms and/or reduced per-
formance on a pulmonary function test (PFT) under-
went an open lung biopsy and were followed for at least
3 years. Twelve subjects involved in the previous study
[6] were selected (sixteen samples were not included due
to lack of lung material for miRNA isolation). The
patients included in the current study were classified
as having diffuse SSc (dSSc) (n = 7) and limited SSc
(lcSSc) (n = 5), according to diagnostic [10] and sub-
type criteria [11]. Controls were five samples of nor-
mal histological healthy lung tissue obtained during
lung cancer surgical resection. Lung explants from
controls and patients with SSc-ILD were obtained
from lung transplants at the University of Pittsburgh
Medical Center (healthy controls, n = 6; SSc-ILD, n = 6)
and used for fibroblast culture. Peripheral blood mono-
nuclear cells (PBMC) were collected from healthy controls
(n = 6) and patients with SSc-ILD (n = 13) from Boston
University Medical Center. Informed consent was ob-
tained from all patients and healthy subjects involved in
the study. The Boston University Medical Center, the
University of Sao Paulo, and the University of Pittsburgh
Institutional Review Boards reviewed and approved the
conduct of this study.
Histological diagnosis
Two pathologists (VLC and ERP) classified the lung
specimens as previously described [6].
High-resolution computed tomography
Two pulmonologists (CRC and RC) performed
blinded evaluation of the images. As described previ-
ously [6] each lung was divided into three zones:
upper (lung apex to aortic arch); middle (aortic arch
to inferior pulmonary veins); and lower (inferior
pulmonary veins to lung bases). For baseline and
follow up HRCT, the extent of the pulmonary abnor-
mality was scored as previously described [6]. The
sum of all scores on the lung zones is referred to as
FibMax. A delta FibMax, which is the difference
between the follow-up FibMax and the baseline Fib-
Max, was used to evaluate the progression of the
lung fibrosis.
Lung biopsy
Open lung biopsy was performed by formal thoracot-
omy, avoiding honeycombing areas [6].
Follow up
Patients with evidence of non-specific interstitial pneu-
monia (NSIP) on lung biopsy were treated with monthly
intravenous cyclophosphamide (0.5–1.0 g/m2) for at
least one year (see previous report for details [6]). HRCT
and PFT were performed before biopsy and repeated
2–3 years after the one-year treatment (Fig. 1a).
RNA and microRNA isolation and microarray analysis
hybridization
Total RNA and miRNA from human lung biopsy tissue,
lung fibroblasts, and PBMC were extracted using micro-
RNeasy Mini Kits (Qiagen). RNA samples were stored
at –80 °C.
MicroRNA and messenger RNA quantitative PCR (qPCR)
Complementary DNA (cDNA) was transcribed using the
TaqMan MicroRNA Reverse Transcription Kit (Life
Technologies) and Reverse Transcriptase (Gibco BRL)
and primers using 200 ng of total RNA and according to
the manufacturer’s protocol. Samples were diluted 1:15
and followed the TaqMan Universal PCR Master Mix
(Life Technologies) protocol. Specific miRNA primers
were used for miR-155, miR-21, miR-182, miR-15b,
miR-193a, and RNU6B (Life Technologies). Specific
mRNA primers were used for collagen type 3 alpha-1
(Col3a1), MS4A4A, periostin (POSTN), and 18S (Life
Technologies). miRNA and mRNA qPCR was performed
using the TaqMan assay and StepOne Plus Real Time
PCR system (Applied Biosystems) in a 20-ul reaction for
40 cycles. Gene expression was analyzed using the differ-
ence in cycle threshold (ΔCt) method. The Ct values of
the miRNAs were normalized to RNU6B and of the
mRNA were normalized to 18S as an internal control
using the equation:
ΔCt = Ct reference – Ct target and expressed as ΔCt.
Microarray data clustering
All procedures were performed at Boston University
Microarray Resource Facility as described in the Affymetrix
GeneChip 3′IVT Express user manual (Affymetrix, Santa
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Clara, CA, USA; www.affymetrix.com). For mRNA
arrays biotin-labeled amplified total RNA was purified,
fragmented, and hybridized to Affymetrix U133A 2.0
microarrays. The MAS5 algorithm with global scaling
normalization was used to generate gene-level expression
data. For miRNA arrays miRNA was purified, fragmented
and hybridized to Affymetrix GenChip miRNA 3.0
microarrays. The signal of the samples was amplified and
microarrays were immediately scanned using Affymetrix
GeneArray Scanner 3000 7G Plus (Affymetrix, Santa Clara,
CA, USA). The resulting CEL files were summarized using
the Affymetrix Expression Console (current version 1.1).
Clustering was performed using Cluster 3.0 software. Both
mRNA and miRNA Affymetrix data [GEO:GSE81294]
and SubSeries linked to GSE81294 [GEO:GSE81292;
GEO:GSE81293] are available at the public repository
Gene Expression Omnibus. Additional file 1: Table S1
and Additional file 2: Table S2 contain all the miRNA
Fig. 1 a Timeline of the study. See “Methods” for more details. b Heatmap of whole lung homogenate showing the expression of genes clustered
using complete linkage hierarchical supervised clustering. Gray indicates healthy controls (HC1 to HC5; n = 5); orange indicates patients with systemic
sclerosis interstitial lung disease (SSc-ILD) (SSc-A to SSc-K; n = 12). Each miRNA was z-score-normalized across all samples and was scaled to red and blue
(≥2 or ≤ –2, respectively) and white indicating a z score of zero. ILD interstitial lung disease, HRCT high-resolution computer tomography, PFT pulmonary
function test, FibMax HRCT lung score, FVC% percent forced vital capacity, NSIP non-specific interstitial pneumonia
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and mRNA, respectively, that were significantly differ-
ent in patients with SSc-ILD and controls.
Fibroblast culture
Lung tissue was minced and primary fibroblasts cultured
using the outgrowth method as previously described
[12]. Lung fibroblasts were cultured in DMEM supple-
mented with 10 % fetal bovine serum and penicillin/
streptomycin and utilized at passages 2–4. Fibroblasts
(100 % confluent) were incubated in serum-free DMEM
overnight prior to stimulation with TGFß (R&D System;
2.5 ng/ml), recombinant human IL-13 (R&D Systems,
20 ng/ml), or interferon-alpha (IFN) (R&D Systems;
500 U/ml) for 18 hours. Total RNA from fibroblasts was
transferred in Qiazol buffer and purified using the miR-
Nease mini kit protocol (Qiagen). RNA samples were
stored at –80 °C.
Peripheral blood mononuclear cells
Blood was collected in cell preparation tubes (CPTs) de-
signed for one-step cell separation (Becton Dickinson)
from healthy controls and patients within 3 months of
the date when the lung function tests were performed.
The sample was immediately mixed and centrifuged at
1800 g at ambient temperature for 30 minutes. Total
RNA from PBMC was extracted using the miRNease
mini kit protocol (Qiagen). RNA samples were stored
at –80 °C.
MicroRNA Nanostring technology
RNA (100 ng from each sample) was used for the
miRNA analysis. The miRNA library contains 800 of the
most relevant miRNA described in the literature.
Normalization was performed using the average of
expression of the top 20 most-expressed miRNA in all
samples. The minimal threshold for the detection of
miRNA was considered as 50 counts.
RNA Nanostring technology
RNA (100 ng of from each mouse) was used for RNA
analysis. The lung gene panel was built based on a
microarray analysis of the lungs of mice exposed to a
bleomycin-pump compared to PBS in previous experi-
ments (unpublished results). Normalization was per-
formed using nine housekeeping genes that were not
affected by the bleomycin-pump model.
DNA Intelligent Analysis (DIANA) DIANA-miRPath
v2.0 utilizes miRNA targets based on DIANA-microT-
CDS, which predicts miRNA-gene interaction including
the binding region, position, and type, and/or miRNA-
gene interaction experimentally validated from Tarbase
v7.0 [13]. Combined analysis results for miRNA and
pathway-related information was obtained from miRBase
18 [14] and the Kyoto Encyclopedia of Genes and Genomes
(KEGG) v58 [15]. The selected top 30 upregulated and
downregulated miRNA were used (Additional file 1:
Table S1).
Bleomycin lung fibrosis model
C57BL/6 J (B6) and B6.Cg-Mir155tm1.Rsky/J mice were
purchased from The Jackson Laboratory (Bar Harbor,
ME, USA). Age-matched and sex-matched mice were
used in the experiments at 8 to 10 weeks. Mice were
kept in pathogen-free conditions with food and water.
The in vivo study was approved by the Animal Ethics
Committee at the Boston University School of Medicine.
Mice were chronically exposed to PBS or Bleomycin
(90 U/Kg) by subcutaneous osmotic pump injections for
7 days. Mice were observed and sacrificed on day 28. The
survival curve was calculated. Lungs were harvested for
histology and gene expression. H&E and Masson’s
Trichrome staining were performed. The Ashcroft lung
score was measured blinded by one investigator (RBC).
Statistical analysis
Data analysis was performed using GraphPad Prism 6
software, version 6.0a (GraphPad Software, San Diego,
CA, USA). Multiple group comparisons were analyzed by
one-way analysis of variance (ANOVA) with Bonferroni
adjustment for multiple comparisons. Two-group compar-
isons were analyzed by Student’s t test or the Mann-
Whitney test. Correlation was tested and presented as
Pearson’s correlation coefficient (r). The survival fraction
was calculated by the Kaplan-Meier test with 95 % confi-
dence intervals computed by the asymmetrical method
using the log-rank test.
Results
Baseline characteristics of patients with systemic sclerosis
interstitial lung disease
A timeline of the study is summarized in Fig. 1a. We
have previously described all the demographic and
FibMax data of these patients with SSc-ILD before and
after treatment [6]. Note that despite treatment, most
patients with SSc-ILD developed progressive disease
based on the FibMax, with a mean baseline score of
6.88 ± 4.47 compared to 12.76 ± 6.59 after treatment;
p = 0.006. The delta FibMax was used to gauge the pro-
gression of lung fibrosis as previously described [6].
Healthy control lungs were obtained from cancer-free
resected lungs.
Patients with systemic sclerosis interstitial lung disease
have distinct microRNA gene expression patterns
We analyzed lung tissue samples from healthy controls
(n = 5) and patients with SSc-ILD (n = 12) using miRNA
microarrays. Both middle and lower lobe samples were
analyzed in five of the patients with SSc-ILD, while only
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the lower lobes were analyzed in seven patients. One
patient was excluded from the miRNA analysis on the
basis of poor quality metrics. To identify genes with dif-
ferential expression associated with SSc-ILD, Student’s
two-sample t test was performed to compare SSc-ILD
(expression averaged for each gene from both lung
biopsy sites) and control samples (p < 0.05). A false
discovery rate (FDR)-corrected p value (q < 0.25) was
computed after removing miRNA present in ≤25 % of
the samples, to eliminate miRNA with low overall
expression. A heatmap of the most informative miRNA
(n = 185 genes) was created containing the miRNA with
the most significant differential expression between SSc-
ILD and control samples. Most of the miRNA were
downregulated in patients compared to the healthy con-
trols (Fig. 1b). The complete list of significantly different
miRNA can be found in Additional file 1: Table S1.
We validated several miRNA that were upregulated in
patients with SSc-ILD compared to the controls, by qPCR.
miR-182 was highly expressed in the lung tissue from
patients with SSc-ILD (mean fold-change 17.5 ± 14.8) com-
pared to controls (mean fold-change 1.1 ± 0.6; p = 0.001.
Fig. 2a). miR-155 was upregulated in patients with SSc-ILD
(mean fold-change 7.6 ± 9.2) compared to controls (mean
fold-change 1.0 ± 0.5; p = 0.003. Fig. 2b), and miR-21 was
upregulated in patients with SSc-ILD (mean fold-change
3.4 ± 2.6) compared to controls (mean fold-change
1.1 ± 0.7; p = 0.06), although not statistically signifi-
cant (Fig. 2c).
Validation of relevant gene signatures in systemic
sclerosis interstitial lung disease
In order to better understand the potential mRNA tar-
geted by altered lung miRNA expression, we analyzed all
samples for mRNA expression by microarray. We identi-
fied genes with differential expression associated with
SSc-ILD, using Student’s two-sample t test (p < 0.05)
corrected by FDR (q < 0.25). These microarray data con-
firmed the altered expression of hundreds of genes in
SSc-ILD that we reported previously [6], such as chemo-
kine C-C motif ligand 18 (CCL18), several collagens
(types I and III), macrophage activation markers (for
example, CD163 and MS4A4A), secreted phosphopro-
tein 1/osteopontin (SPP1), and others (Additional file 2:
Table S2). Using qPCR, we validated several of the top
upregulated genes in lung tissue from patients with
SSc-ILD, such as COL3a1 (p = 0.004), MS4A4A (p = 0.02),
and POSTN (p = 0.006) Fig. 2d-f.
Messenger RNA and microRNA: a complex network
Taking advantage of our simultaneous analysis of mRNA
and miRNA in the same cohort of patients with SSc-ILD
Fig. 2 Whole lung homogenate with miRNA and mRNA expression by qPCR of miR-182 (a), miR-155 (b), miR-21 (c), collagen type 3 alpha-1
(Col3a1) (d), MS4A4A (e), and periostin (POSTN) (f) in healthy controls (HC) (n = 5) and patients with systemic sclerosis interstitial lung disease
(SSc-ILD) (n = 14). Data are expressed as fold-change normalized to miRNA (RNU6B) or mRNA (18S) average expression in HC samples. Student’s t test;
p < 0.05 was considered significant
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and healthy controls we further investigated interactions
between mRNA and miRNA lung expression. Pearson’s
correlation was tested between selected upregulated and
downregulated miRNA (see Additional file 1: Table S1)
and the most highly upregulated and downregulated
mRNA in SSc-ILD (see Additional file 2: Table S2) by
microarray analysis, based on average fold-change gene
expression compared to controls. miR-155, miR-21, and
miR-4459 were the miRNA that were most strongly cor-
related and their interactions are shown in Table 1.
RNA and microRNA: pathway analysis
We selected the top upregulated and downregulated
miRNA in patients with SSc-ILD compared to the
controls (see Additional file 1: Table S1) for pathway
analysis. First, we applied the DIANA-Tarbase v7.0
database in order to identify miRNA target genes experi-
mentally validated in the literature (see “Methods”).
Only a few miRNA from the selected group had vali-
dated target genes: miR-155, miR-21, miR-125a, miR-31,
miR-205, miR-20a, let-7f, miR-182, let-7e, miR-199b,
miR-199a, miR-663, and miR-193a. miR-155 (n = 812)
and miR-21 (n = 581) had the largest list of target genes
already validated.
To gain further insight into the function of the top
dysregulated miRNA and their targets, DIANA-microT-
CDS miRPath was applied to identify the significant
KEGG pathways (see “Methods”): 57 KEGG biological
processes were significantly enriched (p < 0.05, FDR-
corrected) in SSc-ILD (Additional file 3: Figure S1). The
10 most highly implicated processes identified using this
approach, with their related miRNA, can be found in
Table 2.
miR-155 lung expression correlates with progressive
systemic sclerosis interstitial lung disease
There is an urgent need for a biomarker that predicts
the progression of lung fibrosis in patients with SSc.
miRNA are known to regulate a complex network;
therefore, we tested the correlation between miRNA
microarray lung gene expression and changes in the lung
fibrosis score FibMax, the sum of all fibrotic scores in
the six lung zones (see “Methods”). The delta FibMax of
each patient, when available, was correlated with corre-
sponding patient lung miRNA microarray fold-change
gene expression (see Additional file 1: Table S1). Surpris-
ingly, only four miRNA correlated positively with the
delta FibMax (r > 0.4) with miR-155 having the strongest
correlation (r = 0.65, p < 0.001, Fig. 3a), followed by
miR-182 (r = 0.49, p = 0.06), miR-27a (r = 0.49, p = 0.06),
and miR-21 (r = 0.47, p = 0.07). Five miRNA correlated
negatively with the delta FibMax, with miR-143 having the
strongest negative correlation (r =–0.64, p < 0.01), followed
by miR-4270 (r = –0.59, p = 0.01), miR-4530 (r = –0.54,
p = 0.03), miR-19b (r = –0.51, p = 0.05), and miR-4459
(r = –0.50, p = 0.05).
miR-155 expression by peripheral blood mononuclear
cells is correlated with progressive systemic sclerosis
interstitial lung disease
PBMC gene expression has been used as a surrogate for
rarely available lung tissue to further investigate lung
complications in SSc, such as SSc-ILD and SSc pulmonary
arterial hypertension (SSc-PAH) [16]. Therefore, we ana-
lyzed miRNA expression in SSc-ILD (n = 13) and control
PBMC (n = 5) by Nanostring; demographic features are
shown in Additional file 4: Table S3. Among the miRNA
that were upregulated in the lungs of patients with SSc-ILD
(Additional file 1: Table S1) let-7d (p = 0.01), miR-15b (p =
0.05), and miR-21 (p = 0.1) were the most expressed in
PBMC from SSc-ILD compared to controls (Additional file
5: Table S4) based on fold-change expression.
More importantly, we observed that miR-155 expres-
sion on SSc-ILD PBMC was strongly negatively corre-
lated with both %FVC (r = –0.60; p = 0.01) and %DLCO
(r = –0.58; p = 0.02). let-7d was also strongly negatively
correlated with %FVC (r = –0.65; p = 0.007) and with
%DLCO (r = –0.56; p = 0.02). miR-21 PBMC expression
did not correlate with lung function tests (%FVC r = 0.14;
%DLCO r = 0.18; both p > 0.05).
Activated lung fibroblasts have minor influence on the
microRNA signature in systemic sclerosis interstitial
lung disease
In order to elucidate whether fibroblasts might be re-
sponsible for the miRNA expression in SSc-ILD we
stimulated healthy lung fibroblasts (n = 6) and fibroblasts
from the lungs of patients with SSc-ILD (n = 6) with cy-
tokines known to be involved in the progression of lung
disease: TGFβ, IL-13, and IFN [6]. Fibroblasts were stim-
ulated for 18 hours and miRNA expression was analyzed
by Nanostring technology (Additional file 6: Table S5)
and confirmed in a larger number of samples by qPCR
(see “Methods”).
Expression of miR-21 was in general slightly increased
after IFN and TGFβ stimulation of fibroblasts in SSc-ILD,
although not statistically significant (Fig. 3d, p > 0.05). On
the other hand, miR-155 expression was reduced overall
after all three stimuli of fibroblasts in SSc-ILD, although
not statistically significant (Fig. 3e, p > 0.05). There was
mild expression of miR-193a and miR-15b in lung
fibroblasts in both groups after all three stimuli (Additional
file 7: Figure S2A and B, respectively).
The absence of miR-155 protects mice from
bleomycin-induced lung fibrosis
We observed that miR-155 expression in the lungs and
in the blood of patients with SSc-ILD are strongly
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Table 1 Strongest positive and negative correlation between the most expressed messenger RNA (top upregulated and downregulated
genes) and miR-155/miR-21/miR-4459 lung expression
Abbreviation Gene name Fold-change r (miR-155) r (miR-21) r (miR-4459)
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) 14.1 0.13 0.24 -0.52
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) 12.0 0.57 0.54 -0.85
KRT15 Keratin 15 7.1 0.27 0.40 -0.51
S100A2 S100 calcium binding protein A2 6.6 0.29 0.45 -0.57
PDIA3 Protein disulfide isomerase family A, member 3 6.2 0.67 0.52 -0.76
CDH3 Cadherin 3, type 1, P-cadherin (placental) 5.6 0.60 0.60 -0.82
IL13RA2 Interleukin 13 receptor, alpha 2 5.6 0.75 0.81 -0.78
IGHM Immunoglobulin heavy constant mu 5.5 0.67 0.52 -0.63
SPP1 Secreted phosphoprotein 1 5.1 0.69 0.55 -0.74
GPR87 G protein-coupled receptor 87 4.7 0.29 0.32 -0.45
RRM2 Ribonucleotide reductase M2 4.7 0.72 0.59 -0.57
CTSE Cathepsin E 4.4 0.66 0.66 -0.91
AADAC Arylacetamide deacetylase 4.4 0.60 0.48 -0.76
CXCL6 Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2) 4.3 0.34 0.34 -0.30
CR2 Complement component (3d/Epstein Barr virus) receptor 2 4.2 0.61 0.37 -0.42
TYMS Thymidylate synthetase 4.2 0.72 0.58 -0.75
CXCL13 Chemokine (C-X-C motif) ligand 13 4.1 0.77 0.59 -0.48
SCG5 Secretogranin V (7B2 protein) 4.1 0.76 0.70 -0.70
MEOX1 Mesenchyme homeobox 1 3.9 0.59 0.52 -0.51
TOP2A Topoisomerase (DNA) II alpha 170 kDa 3.7 0.68 0.62 -0.64
POSTN Periostin, osteoblast specific factor 3.7 0.74 0.70 -0.74
Pearson’s correlation >0.5 or < -0.5 total n = 16 n = 14 n = 17
IL6 Interleukin 6 (interferon, beta 2) -45.2 -0.50 -0.44 0.54
SERPINE1 Plasminogen activator inhibitor type 1, member 1 -21.9 -0.45 -0.36 0.60
FOSB FBJ murine osteosarcoma viral oncogene homolog B -18.4 -0.69 -0.66 0.73
MT1M Metallothionein 1 M -15.8 -0.50 -0.41 0.54
DDX3Y DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked -14.3 -0.17 -0.51 0.33
RND1 Rho family GTPase 1 -13.6 -0.46 -0.37 0.40
IL8 Interleukin 8 -12.8 -0.40 -0.26 0.37
NXF3 Nuclear RNA export factor 3 -12.0 -0.80 -0.75 0.89
CSF3 Colony stimulating factor 3 (granulocyte) -11.8 -0.50 -0.34 0.48
CCL2 Chemokine (C-C motif) ligand 2 -11.6 -0.47 -0.36 0.54
PTX3 Pentraxin 3, long -11.4 -0.15 -0.02 0.27
IL12A Interleukin 12A -11.1 -0.70 -0.64 0.85
CCL20 Chemokine (C-C motif) ligand 20 -9.5 -0.25 -0.17 0.15
GADD45B Growth arrest and DNA-damage-inducible, beta -9.5 -0.50 -0.42 0.54
ESM1 Endothelial cell-specific molecule 1 -8.6 -0.52 -0.36 0.48
CXCL2 Chemokine (C-X-C motif) ligand 2 -8.5 -0.40 -0.44 0.46
SLC6A4 Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 -8.4 -0.82 -0.87 0.72
SLCO4A1 Solute carrier organic anion transporter family, member 4A1 -8.3 -0.62 -0.50 0.64
KDM5D Lysine (K)-specific demethylase 5D -8.2 -0.15 -0.48 0.37
S100A12 S100 calcium binding protein A12 -8.2 -0.45 -0.33 0.53
HAS2 Hyaluronan synthase 2 -8.2 -0.29 -0.27 0.30
Pearson’s correlation >0.5 or < –0.5 total n = 9 n = 6 n = 10
In sequence: gene symbol, gene name, average fold-change expression in SSc-ILD compared to healthy controls, r values for correlation between each gene and
specific miRNA
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correlated with progressive lung disease identified by
image and by lung function tests, respectively. There-
fore, we tested the bleomycin model of chronic lung fi-
brosis in mice deficient in miR-155 (miR-155 knockout
(KO)) compared to wild-type mice (WT). miR-155 KO
mice had a 100 % survival rate over the course of 28 days
after starting bleomycin compared to a 45 % survival
rate in WT mice; p < 0.001, log-rank test (Fig. 4a). WT
(n = 7) and miR-155 KO (n = 6) mice exposed to PBS
were used as controls. WT (n = 11) and miR-155 KO (n
= 11) mice were exposed to bleomycin and three WT
mice were found dead on days 8, 13, and 17, respect-
ively. One WT mouse exposed to bleomycin was killed on
day 20 due to poor conditions and was included in the
lung Nanostring analysis. miR-155 KO mice (n = 11)
developed milder fibrosis in the lungs as measured by the
Ashcroft lung score (Fig. 4b, p < 0.001) compared to the
WT (n = 7) exposed to bleomycin on day 28.
We tested the effect of miR-155 deletion on
bleomycin-induced gene expression using a custom-
designed Nanostring that we developed to detect pro-
inflammatory and profibrotic genes upregulated in the
lungs of bleomycin-treated lung tissue and lung tissue
from patients with SSc-ILD. Overall, bleomycin-induced
lung gene expression was lower in miR-155 KO mice
(Additional file 8: Figure S3). Arginase-1 lung gene
expression was strongly induced in the WT mice and
correlated positively with the Ashcroft score (r = 0.70,
p < 0.001). Arginase-1, a marker of M2 macrophages
(Fig. 4c), and tissue inhibitor of metalloproteinase-1
(TIMP1) lung expression (Fig. 4d) were induced signifi-
cantly less after bleomycin in miR155 KO mice compared
to WT mice. Expression of other bleomycin-induced
genes was blunted in miR-155 KO lungs compared to WT
mice and clustered with Arginase-1 and TIMP1 (Fig. 4e).
On the other hand, expression of CD68, a general marker
Table 2 Top 10 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to the most expressed microRNA in the lungs
of patients with systemic sclerosis interstitial lung disease compared to controls
KEGG pathway p value #genes miRNA
ECM-receptor interaction (hsa04512) <1e-16 16 3 let-7e, miR-4459, let-7f
Ubiquitin mediated proteolysis (hsa04120) <1e-16 76 9 miR-182, miR-141, miR-125a, miR-379, miR-4484,
miR-574, miR-3613, miR-4739, miR-20a
Wnt signaling pathway (hsa04310) <1e-16 79 10 miR-155, miR-205, miR-1224, let-7e, miR-4459,
miR-762, miR-4668, let-7f, miR-3613, miR-20a
MAPK signaling pathway (hsa04010) <1e-16 132 13 miR-21, miR-155, miR-125a, let-73, miR-4530,
miR-1207, miR-149, miR-762, let-7f, miR-199a,
miR-199b, miR-3613, miR-20a
Pathways in cancer (hsa05200) <1e-16 166 15 miR-21, miR-155, miR-182, miR-205, miR-1224,
let-7e, miR-4459, miR-4484, let-7f, miR-199a,
miR-574, miR-199b, miR-3613, miR-4739, miR-20a
Axon guidance (hsa04360) 7.77E-16 72 11 miR-155, miR-205, miR-1224, miR-379, miR-4741,
miR-762, miR-4689, miR-4484, miR-3613, miR-4739,
miR-20a
PI3K-Akt signaling pathway (hsa04151) 2.74E-14 137 12 miR-155, miR-182, let-7e, miR-379, miR-4459,
miR-149, miR-4668, let-7f, miR-199a, miR-199b,
miR-3613, miR-20a
TGF-beta signaling pathway (hsa04350) 5.88E-14 41 10 miR-21, miR-205, let-7e, miR-4668, miR-451a,
miR-4484, let-7f, miR-3613, miR-20a, miR-455
ErB signaling pathway (hsa04012) 1.17E-13 40 12 miR-155, miR-205, miR-193a, miR-200b, miR-4530,
miR-451a, miR-4484, miR-199a, miR-199b, miR-200c,
miR-3613, miR-20a
Transcriptional misregulation in cancer (hsa05202) 1.23E-13 83 11 miR-182, miR-205, miR-1224, let-7e, miR-1207,
miR-149, miR-4668, let-7f, miR-3613, miR-20a,
miR-455
In sequence: pathway names, significance levels based on p value, number of targeted genes, number of miRNA targeting each pathway, and list of miRNA related to
each pathway
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of macrophages, was induced similarly in both groups
exposed to bleomycin (p > 0.05).
Discussion
Dysregulation of the immune system is critical for the
development of skin and lung involvement in SSc. In
this regard, we have recently shown that this inappropri-
ate inflammatory response in the lungs is strongly corre-
lated with progressive lung fibrosis [6], along with a
profibrotic TGFβ signature. miRNA are a new class of
regulators that tightly control the overall inflammatory
response. We show here that miRNA are intensely dys-
regulated in the lungs and in PBMC in patients with
SSc-ILD. Moreover, we found that dysregulated gene
expression of only a few miRNA, including miR-155, are
strongly associated with progressive lung disease and
that the absence of miR-155 is protective for the
bleomycin-lung fibrotic model.
miR-155 controls differentiation of CD4+ T cells into
its several subtypes to regulate B-cell differentiation and
antibody production, and is highly expressed in activated
monocytes/macrophages [17]. miR-155 is upregulated in
several autoimmune disorders, such as rheumatoid
arthritis [18], multiple sclerosis [19], systemic lupus
erythematosus [20, 21], and ulcerative colitis [22]. In our
cohort, we showed that miR-155 expression correlates
highly with profibrotic gene expression, such as SPP1
and POSTN. We also observed strong correlation
between miR-155 PBMC expression in patients with
SSc-ILD and lung function tests. On the other hand,
lung fibroblasts seem not to be the most relevant cell
type driving the strong expression of miR-155 in the
lungs in patients with SSc-ILD.
We showed the functional relevance of miR-155 in
lung fibrotic disease where miR-155 KO mice survived
longer and developed substantially less aggressive lung
fibrosis based on lung phenotype and on a comprehen-
sive lung gene expression analysis. This protective effect
might be underestimated as three mice in the WT bleo-
mycin group did not survive until day 28 and neither
the lung score nor the lung gene expression were
considered in the analysis. In addition, the absence of
miR-155 in the model blocked the alternative activation
of lung macrophages, which correlates strongly with
Fig. 3 a Correlation between the delta high-resolution computerized tomography lung score (FibMax) and mir-155 whole lung homogenate gene
expression (r = 0.65, p < 0.001). b Correlation between miR-155 expression on peripheral blood mononuclear cells by Nanostring and percentage
forced vital capacity (%FVC) (r = –0.60, p = 0.01), and c percentage diffusing capacity of the lung for carbon monoxide (%DLCO) (r = –0.58, p = 0.02).
d miR-21 and e miR-155 expression on lung fibroblasts from cell lines of healthy controls (HC) and patients with systemic sclerosis interstitial lung
disease (SSc-ILD) stimulated for 18 hours with media, IL-13, transforming growth factor-beta (TGF-β), and interferon-alpha (IFN-α) (see “Methods”)
(analysis of variance, p > 0.05 for both miRNA). Data are expressed as fold-change compared to HC samples or media control on a, b, d, and e.
Data are expressed as counts of gene expression and percentage on b and c. p < 0.05 was considered significant
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Fig. 4 (See legend on next page.)
Christmann et al. Arthritis Research & Therapy  (2016) 18:155 Page 10 of 13
progressive lung fibrosis in patients with SSc-ILD [6]
and with the Ashcroft lung fibrotic score in our murine
model. Yan et al. [23] recently showed protection of
bleomycin cutaneous fibrosis in miR-155-deficient mice
and reduced skin thickness after topical antagomiR-155
treatment in mice primed with subcutaneous bleomycin
[23]. In the intratracheal bleomycin murine lung model
miR-155 was upregulated and correlated with the degree
of lung fibrosis [24]. Altogether, our observations rein-
force the hypothesis of a strong immune activation in
SSc-ILD with miR-155 as a key regulator.
Our observations that miR-21 is upregulated in the
lungs of patients with SSc-ILD suggest that modulating
miR-21 might be a future therapeutic strategy for SSc-
ILD. miR-21 has been extensively studied in fibrosis,
with increased expression observed in the lungs of
bleomycin-treated mice and in the lungs of patients with
idiopathic pulmonary fibrosis (IPF) in whom it is mainly
localized in myofibroblasts [25]. More importantly, re-
storing miR-21 to normal levels inhibits bleomycin-
induced pulmonary fibrosis [25]. miR-21 is also upregu-
lated in the skin and fibroblasts from patients with both
diffuse and limited subtypes of SSc [26]. miR-21 is in-
duced by TGFβ in stellate hepatic cells and in a feed-
forward loop it amplifies its signal, eventually promoting
fibrosis [27]. Lung fibroblasts might not be the main cell
type responsible for the miRNA signature in SSc-ILD, as
we observed only a slight increase in miR-21 expression
after TGFβ stimulation. Although our data on lung
tissues in SSc-ILD do not permit a direct assessment of
intracellular pathways, we showed that several upregu-
lated profibrotic genes, such as Col3a1 and POSTN,
correlate positively with miR-21 lung expression. In
addition to being well-established as a profibrotic-
miR, miR-21 is also central to many inflammatory
pathways, and most importantly, in controlling the
Toll-like receptor signaling with strong connection
with miR-155 [28].
We also showed for the first time that miR-182 is upreg-
ulated in the lungs of patients with SSc-ILD. miR-182 has
been implicated in several types of cancer and it is known
to regulate proliferation, invasion, and migration of cancer
cells [29]. Interestingly enough, some of the recently iden-
tified miR-182 targets are strong inhibitors of extracellular
matrix degradation [30]. miR-4484 and miR-4459 were
significantly downregulated in our cohort of patients with
SSc-ILD and neither of them have validated target genes
based on Tarbase v7.0 [13].
Our study has limitations. Our cohort was small and
our results should ideally be validated in a larger group.
The suggested mRNA-miRNA interactions and pathways
are mainly predicted, although our agnostic and unbiased
analysis using algorithmic tools guided us in similar direc-
tions, which support the validity of our results.
Conclusions
Our unique approach of analyzing the relevance of
miRNA in SSc-ILD using gene expression, pathway ana-
lysis, and functional studies, revealed a selected group of
miRNA that might mediate the development and/or the
progression of SSc-ILD. miR-155 and miR-21 were the
most relevant miRNA having in common a close involve-
ment in altered pathways observed in fibrotic diseases.
mir-155 regulates the development of lung fibrosis in
mice, thus, opening a new drug development opportunity.
Additional files
Additional file 1: Table S1. The 185 differential miRNA expression
(present in ≥25 % of samples, q < 0.25) in average fold-change observed
in SSc-ILD compared to healthy controls. In sequence: transcript ID,
fraction of samples. Top 30 upregulated and downregulated miRNA
(present in >80 % of samples, p < 0.05) are highlighted in bold. (XLSX 55 kb)
Additional file 2: Table S2. List of mRNA gene expression in SSc-ILD
compared to healthy controls. In sequence: gene symbol, gene name,
and average fold-change expression in SSc-ILD compared to healthy
controls. (XLSX 15 kb)
Additional file 3: Figure S1. List of the 57 KEGG pathways related to the
most expressed miRNA in the lungs of patients with SSc-ILD compared to
controls. In sequence: pathway names, significance levels based on p value,
number of targeted genes, number of miRNA targeting each pathway.
(PDF 1456 kb)
Additional file 4: Table S3. Demographic data of patients with SSc-ILD
and healthy controls for the miRNA analysis in PBMC. %FVC percentage
forced vital capacity. %DLCO percentage diffusing capacity of the lung for
carbon monoxide, LSSc limited systemic sclerosis, DSSc diffuse systemic
sclerosis. (XLSX 35 kb)
Additional file 5: Table S4. miRNA expression in PBMC by Nanostring
analysis. Data are expressed as counts ofgenes and fold-change of the
average on PBMC in SSc-ILD compared to the average of the controls
(column U). (XLSX 167 kb)
Additional file 6: Table S5. miRNA expression in lung fibroblasts by
Nanostring analysis. Healthy control lung fibroblasts (HC) and SSc-ILD
lung fibroblasts were stimulated with media, interleukin-13 (IL-13),
interferon alpha (IFN), and TGF-beta for 18 hours. Data are expressed as
counts of gene expression. (XLSX 56 kb)
(See figure on previous page.)
Fig. 4 Milder lung fibrosis in miR-155 knockout (KO) mice. a Percent survival rate by Kaplan-Meier, log-rank test. b Ashcroft lung score assessed
by Masson’s trichrome staining. Lung gene expression by Nanostring of Arginase-1 (c) and tissue inhibitor of metalloproteinase-1 (TIMP1) (d).
e Cluster of the most affected genes by the absence of miR-155 (blue). Data are expressed by counting gene expression on c and d. Each microRNA
was z-score-normalized across all samples and scaled to red and blue (≥2 or ≤ –2, respectively) and white indicating a z score of zero. Analysis of
variance; p < 0.05 was considered significant. WT wild-type, Bleo bleomycin
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Additional file 7: Figure S2. miRNA expression of miR-193a (A) and
miR-15b (B) on lung fibroblasts from cell lines of healthy controls (HC)
and patients with SSc-ILD stimulated for 18 hours with media, IL-13,
TGF-beta, and IFN-alpha. Data are expressed as fold-change compared
to HC samples or media control. ANOVA, p > 0.05 for both miRNAs.
(TIF 1112 kb)
Additional file 8: Figure S3. Cluster of genes analyzed on lungs from
wild-type and miR-155 KO mice exposed to PBS or bleomycin (see “Methods”).
Two main clusters of genes upregulated (A) and downregulated (B) on
lungs from wild-type mice exposed to bleomycin on day 28 of the model.
Each miRNA was z-score-normalized across all samples and scaled to red
and blue (≥2 or ≤ –2; respectively) and white indicating a z-score of zero.
(TIF 3423 kb)
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